Speakers

Agathe Michel-De-Cazotte

Andrew Hutchinson

Aoife Murphy

Arvid van Oorschot

Brian Goldberg

Brian M. Goldberg is a Counsel in Dechert LLP’s intellectual property practice with a focus on life sciences patent litigation. Mr. Goldberg has successfully litigated patent cases through bench and jury trials, as well as parallel PTAB proceedings, with vast experience litigating Hatch-Waxman Act ANDA infringement actions. Mr. Goldberg has extensive first-hand experience applying the doctrine of equivalents in patent litigations involving small molecule and biologic pharmaceutical products. Mr. Goldberg’s neuroscience background and deep understanding of the statutory and regulatory framework of the Hatch-Waxman Act provides him invaluable insight in litigating cases to achieve successful outcomes for his clients.

Cecile Goy

Cécile Goy is a member of the Paris Bar focusing on international patent litigation, in particular in the life sciences sector. Before joining Aramis, Cécile worked with an international IP boutique and in-house in the legal department of a car manufacturer. Cécile has also completed an internship at the IP section of the Paris Court of Appeal. Cécile is the author of several articles, including on medical devices and digital therapeutics.

Chris Buntel

Chris Buntel is a US intellectual property attorney with over 20 years experience connecting innovation and intellectual property law. He is a co-founder and the CIPO of Tangibly.  Chris is passionate about trade secrets – the “next big thing” in intellectual property evolution. While other forms of intellectual property have been well supported for years, people are just now realizing the huge need for trade secret management tools and education.  He has a Ph.D. in Organic Chemistry from Stanford University, and J.D. in Law from University of Houston.

Christopher Freeth

Conrad Eckhardt

Conrad practices in the IP field for more than 20 years and gained experience across various industries. Having started with Consumer Products at Procter & Gamble he moved on to Pharmaceuticals at Boehringer Ingelheim and is now active in the medical device field, first as Chief IP Counsel at Leica Biosystems and currently as Chief IP Counsel at Biotronik. Conrad is a European Patent Attorney and a European Patent Litigator and has patent litigation experience in Germany, the USA and China.

Daan De Lange

Denis Schertenleib

Doug McCann

Eleanor Root

Ewan Nettleton

Filipe Pedro

Gaëlle Bourout

Guido Pontremoli

Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.

Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.

Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.

Jako Eleveld

Jenny Davies

Jenny Davies is a life sciences and patent specialist with a Masters in Biochemistry from Oxford. She provides strategic advice to help clients protect and exploit their R&D investment in the life sciences sector, medical device sector and the chemical industry. Her work regularly entails negotiating agreements to support her clients' research, development, manufacture and commercialisation, and protect their markets through the enforcement of patents.

Jenny delivers business-focused solutions across her unique practice area spanning patents and dispute resolution, transactions ranging from strategic licensing to highly complex collaborations and regulatory matters. She advises clients in all aspects of patent enforcement, from technical analysis and global strategy to leading UK litigation and EPO oppositions.

Given the commercial and practical value of the assets Jenny protects, her approach combines precision and detail with a commercial mindset and sector-led solutions. Clients praise her "endless determination", "formidable intellect" and are "deeply impressed" with her "unusual capacity to think creatively".

Her work highlights include leading ground-breaking patent litigation up to the UK Court of Appeal to achieve a novel form of "Arrow declaration" for Fujifilm Kyowa Kirin and advising AstraZeneca across a range of high value and complex transactions: its collaboration with the University of Oxford (COVID-19 vaccine); two $6 billion oncology collaborations with Daiichi Sankyo; an $8.5 billion oncology deal with Merck; and a $300 million oncology deal with Genzyme (Caprelsa).

Jenny is a member of the BioIndustry Association's IP Advisory Committee, and SPC and exclusivities committee, and a regular speaker on patent litigation and strategy.

John Cox

With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.

Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.

John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.

John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.

Kamleh Nicola

Kamleh Nicola is a partner at Marks & Clerk and Co-Head of the firm’s Litigation practice in Canada. Her intellectual property litigation practice centers around patent, trademark, and copyright disputes. Though her client base is broad in scope, she specializes in Health and Life Sciences, working with domestic and multinational pharmaceutical, biopharma, and MedTech organizations. Kamleh is particularly knowledgeable on matters involving Canada’s patent linkage regimes, health regulatory and related compliance, and trade secrets.

Kathleen Fox Murphy

Kevin Feng

Kristin Cooklin

Marc Holtorf

Martina Hufnal

Maximilian Haedicke

Michiel De Bruijn

Mike Gilbert

Mike Gilbert is a partner at Marks & Clerk in London.  He is an Intellectual Property (IP) lawyer who advises clients in a wide variety of business sectors on issues including litigation and dispute resolution, IP strategy and risk limitation, due diligence projects and commercial and licensing transactions involving IP. His primary focus and expertise, however, lies in life sciences patent litigation where he is considered to be one of the UK’s leading practitioners. He has represented some of the world’s leading biopharmaceutical corporations in complex patent and technical disputes including Genentech, Roche, Chugai, Pfizer, Wyeth, AstraZeneca, MedImmune, Daiichi Sankyo, AbbVie, Amgen and Illumina to name but a few. Mike is well known for his strategic and creative vision and is consistently recommended in various legal directories including the World IP Review, Legal 500, Who's Who Legal and the IAM Patent 1000 guide, which describe him as “always at the top of the pile, especially for pharmaceutical matters”. Mike graduated from Cambridge University in 1989 with a degree in chemical engineering.

Naomi Pearce

Naomi Pearce is CEO, Executive Lawyer, Patent & Trade Mark Attorney, and Founder of Pearce IP which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards. With a science background in biology, Naomi has been serving life sciences clients for 25 years.  Among other awards, Naomi is 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Award winner (Life Sciences), 2022 Women in Business Law Asia Pacific “Patent Lawyer of the Year”, 2022 Australasian Lawyer “Most Influential Lawyer”, is ranked in IAM Patent 1000, and a MIP “Patent Star”.

Oscar Lamme

Oya Yalvac

Oya is a Turkish and European Patent Attorney with a background in molecular biology and genetics.

She has worked in the pharmaceutical industry as an in-house patent attorney for more than 10 years.

She is specialized in patent litigation and freedom to operate analysis.

Paul Inman

With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.

Paul provides life science businesses with commercial advice from an international outlook. His specialist experience ideally places him to provide this expertise and client care, with the ultimate aim of delivering well-rounded advice and guidance to ensure the best possible outcome.

As well as litigating in the English courts, he has co-ordinated and advised on IP and regulatory litigation matters across the globe; from all over Europe and the US, to as far afield as Asia, South Africa, Australia and New Zealand.

Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 25 years of litigation in cases leading to more than 40 reported judgments. These range from the tribunals of the UK Patent Office up to the House of Lords, European Patent Office and European Court of Justice.

Paul also has a degree in Molecular Biology and Biochemistry and during his professional career has established an outstanding reputation in the market. He is distinguished in the 2023 edition of IAM Patent 1000: The World's Leading Patent Professionals, ranked individually for both IP law and life sciences law in the peer review publication 'Best Lawyers® in the UK' and recognised in several categories within Chambers & Partners UK 2023.

Petra Bohanec Grabar

Petra Bohanec Grabar is a Slovenian and European Patent Attorney and holds a diploma of Patent Litigation in Europe from the University of Strasbourg.

Petra has extensive experience working in house. In her current role as Group Head in Sandoz, Petra leads a team of patent practitioners supporting development, in licensing and launch of generic products on global markets.

Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana and is an author of twelve peer reviewed articles in the field of pharmacogenetics.

Pierluigi Perrotti

Rebecca Lawrence

Rob Cerwinski

Sean Alexander

Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.

Shohta Ueno

Stefan Luginbuehl

Stefan Luginbuehl, PhD, lawyer, is Head of the Department European Legal Affairs (Dep 5222) at the European Patent Office where he is dealing with a wide range of patent law and patent litigation related subjects, with emphasis on the implementation of the EU unitary patent package into the existing European patent system.

He participated in several Diplomatic and Intergovernmental Conferences on the reform of the European patent system and the international litigation system. He is a lecturer in different universities and is the author and editor of several books and articles on patent procedure and patent litigation in Europe and China.

Takanori Abe

Mr. ABE is an Attorney-at-Law, admitted in both Japan and New York. He is currently a Guest Professor of Osaka University Graduate School of Medicine and formerly a lecturer of The University of Tokyo Graduate School of Medicine and Faculty of Medicine.  He is an arbitrator in Japan and sit on various positions in Japanese medical/pharmaceutical societies.

Mr. ABE works in wide areas of international and corporate matters with a focus on intellectual property law and international commerce. The patent litigations that he has participated covers the fields of pharmaceuticals, chemistry, electronics and machinery, which involve advanced technology such as biotechnology, semiconductors, etc., and which are cross-border matters. He has extensive experience on representing and advising multinational and domestic clients in pharmaceutical industry and is currently involved in the drastic battle between brands and also the one between brands and generics. He also has experience in trademark, copyright and unfair competition litigation.

For Mr. ABE’s detail information and activities, please visit www.abe-law.com or email to: [email protected]

Tjibbe Douma

Wioletta Niwinska

Wioletta Niwińska is a qualified Polish Attorney, well-versed advising clients on legal issues in all aspects of business operations including IP protection, particularly in the new technologies industry, including AI, machine learning, MedTech. She has gained experience working in international and national law firms, the public sector (at the National Centre for Research and Development) and the private sector, however, she decided to work closer to people. She enjoys working with high-growth start-ups and SMEs, helping them develop their innovative ideas in a legally secure environment. Working with creative people motivates her to continuously develop and explore AI and innovation.

Zack Mummery

Zack is a partner at Reddie & Grose and is a UK and European patent attorney based in London.

Zack assists large multinational corporations, SMEs and start-ups operating at the cutting edge of chemistry and pharmaceutical technologies.  

Zack has a wealth of experience drafting new patent applications and managing large patent portfolios covering developed and emerging markets. Zack regularly provides clear commercially focussed advice on global patent strategies, utilising patent protection and managing the risk posed by third party patent rights.

Zack also has experience supporting clients through funding rounds, assisting clients with investor due diligence and he has provided IP support for a number of large deals including a multimillion dollar public offering.